
Bio-Rad Laboratories (BIO) Stock Forecast & Price Target
Bio-Rad Laboratories (BIO) Analyst Ratings
Bulls say
Bio-Rad Laboratories is a leading provider of products and solutions for the clinical diagnostics and life sciences markets. The company's diverse geographic presence and ownership stake in Sartorius, a lab and bioprocessing supplier, provide strong growth potential in the future. Bio-Rad's forecasted sales decline in 2026 does not require an assumption of improving end-market conditions, but rather lapping specific, idiosyncratic headwinds, making it a favorable investment option. Additionally, the company's focus on restructuring and investment in sustainability aligns with positive health outcomes, further strengthening its long-term potential.
Bears say
Bio-Rad Laboratories is facing fundamental headwinds but demonstrates compelling asset value, with its 33% ownership stake in Sartorius likely to increase in optionality following the termination of the Sartorius Trust in mid-2028. One major concern is the company's corporate governance, as the Schwartz family maintains majority ownership and control of the company, potentially leading to misalignment of interests with other shareholders. While Bio-Rad has announced sustainability goals and seeks director competence in sustainability, its integration of sustainability considerations into its strategy is limited. However, the company's core business, which supports disease prevention and diagnostics, is inherently aligned with positive health outcomes. Despite near-term challenges impacting sales growth, Bio-Rad is expected to recover in 2027, as specific headwinds (such as process chromatography and conflict in the Middle East) are expected to be resolved.
This aggregate rating is based on analysts' research of Bio-Rad Laboratories and is not a guaranteed prediction by Public.com or investment advice.
Bio-Rad Laboratories (BIO) Analyst Forecast & Price Prediction
Start investing in Bio-Rad Laboratories (BIO)
Order type
Buy in
Order amount
Est. shares
0 shares